Gamco Investors INC. ET AL Sells 24,100 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Gamco Investors INC. ET AL reduced its stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 18.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 105,600 shares of the company's stock after selling 24,100 shares during the period. Gamco Investors INC. ET AL's holdings in Teva Pharmaceutical Industries were worth $2,327,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Diversify Advisory Services LLC increased its stake in Teva Pharmaceutical Industries by 2.5% during the 4th quarter. Diversify Advisory Services LLC now owns 20,355 shares of the company's stock worth $426,000 after acquiring an additional 496 shares during the period. Sanctuary Advisors LLC boosted its position in shares of Teva Pharmaceutical Industries by 1.9% during the 3rd quarter. Sanctuary Advisors LLC now owns 35,129 shares of the company's stock worth $601,000 after acquiring an additional 664 shares in the last quarter. Thrivent Financial for Lutherans raised its position in Teva Pharmaceutical Industries by 0.3% during the fourth quarter. Thrivent Financial for Lutherans now owns 225,210 shares of the company's stock valued at $4,964,000 after purchasing an additional 699 shares in the last quarter. Townsquare Capital LLC boosted its holdings in shares of Teva Pharmaceutical Industries by 2.1% in the 4th quarter. Townsquare Capital LLC now owns 40,162 shares of the company's stock valued at $885,000 after purchasing an additional 812 shares in the last quarter. Finally, Metis Global Partners LLC raised its holdings in shares of Teva Pharmaceutical Industries by 6.7% during the 4th quarter. Metis Global Partners LLC now owns 13,697 shares of the company's stock worth $302,000 after buying an additional 860 shares in the last quarter. 54.05% of the stock is owned by institutional investors.

Analyst Ratings Changes

TEVA has been the subject of several research analyst reports. Barclays lowered their target price on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating for the company in a research note on Thursday, January 30th. Piper Sandler boosted their price target on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an "overweight" rating in a report on Friday, January 17th. StockNews.com lowered shares of Teva Pharmaceutical Industries from a "buy" rating to a "hold" rating in a report on Monday, April 14th. UBS Group reduced their price objective on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating on the stock in a research note on Thursday, January 30th. Finally, Bank of America lowered their target price on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating for the company in a research report on Thursday, March 6th. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, Teva Pharmaceutical Industries presently has a consensus rating of "Moderate Buy" and an average target price of $23.43.

Teva Pharmaceutical Industries Stock Down 2.6 %

Shares of Teva Pharmaceutical Industries stock traded down $0.35 during trading on Monday, reaching $13.30. 12,058,632 shares of the company traded hands, compared to its average volume of 9,911,346. The company has a debt-to-equity ratio of 2.97, a current ratio of 0.98 and a quick ratio of 0.75. The firm has a market capitalization of $15.08 billion, a PE ratio of -9.17, a P/E/G ratio of 1.44 and a beta of 0.72. The company has a 50 day moving average price of $15.45 and a 200-day moving average price of $17.67. Teva Pharmaceutical Industries Limited has a 1-year low of $12.47 and a 1-year high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its earnings results on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, beating analysts' consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. As a group, equities research analysts expect that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current fiscal year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.